Withdrawal Risk in an Admitted Patient
A 51-year-old man is admitted to the medical floor for cellulitis of the left leg requiring IV antibiotics. He reports drinking "a six-pack most nights" for 20 years and stopped drinking 14 hours ago because he came to the hospital. He also takes alprazolam 1 mg three times daily prescribed by an outside psychiatrist for anxiety. He did not bring his medications. On admission: HR 98, BP 138/84, temperature 37.4°C, tremor of both hands, diaphoresis, and mild disorientation to date. CIWA-Ar score is 12. Labs show elevated AST/ALT, platelets 118,000, and MCV 102. He is pleasant but anxious and asks repeatedly for "something to calm my nerves."
1. What withdrawal syndromes are you managing here, and why is this patient higher risk than the numbers suggest?
Read the worked answer
Two overlapping withdrawal syndromes:
- Alcohol withdrawal - 14 hours since last drink, tremor, diaphoresis, mild disorientation, elevated CIWA-Ar, and a biomarker profile (AST/ALT elevation, thrombocytopenia, macrocytosis) consistent with chronic heavy use.
- Benzodiazepine withdrawal - he is on alprazolam 1 mg three times daily (3 mg/day) and has missed doses since admission. Alprazolam has a short half-life and high potency, so withdrawal can begin within 12–24 hours and escalate quickly.
Why he is higher risk than his vitals suggest:
- Short-acting benzodiazepine plus alcohol - simultaneous withdrawal from two GABAergic agents can be synergistic and can precipitate seizures and delirium.
- Liver disease - elevated transaminases and thrombocytopenia raise concern for impaired hepatic metabolism and coagulopathy, altering drug handling and increasing bleeding risk.
- Thrombocytopenia - relevant to any invasive procedures and to fall risk.
- Mild disorientation - early delirium; this is not "just anxiety."
- Untreated withdrawal can progress to seizures and delirium tremens, which carries significant mortality.
Judgment being tested: identifying the second withdrawal syndrome (benzodiazepine) that is easy to miss when the alcohol history dominates the presentation.
2. Design a monitoring and pharmacologic plan, addressing the fact that his alprazolam is not available and he is asking for medication.
Read the worked answer
Monitoring:
- CIWA-Ar every 4 hours (or more frequently if scores rise), plus vital signs and neurologic checks.
- Delirium screening each shift; orientation checks.
- Fall precautions and seizure precautions.
- Monitor platelets and coagulation given thrombocytopenia and liver disease.
Pharmacologic plan:
- Benzodiazepine is the treatment for both syndromes - this is convenient here. Use a longer-acting agent such as diazepam or chlordiazepoxide in symptom-triggered dosing (e.g., CIWA-guided), or lorazepam if hepatic impairment is a concern (lorazepam undergoes glucuronidation and is safer in liver disease).
- Do not abruptly stop his alprazolam - convert to an equivalent longer-acting benzodiazepine and taper gradually after the acute withdrawal period.
- Thiamine before glucose, folate, and multivitamins; assess nutrition.
- Avoid giving his usual alprazolam dose as a PRN "because he asked" - his request is a symptom, not a prescription.
Addressing the request: explain that he will receive medication to prevent withdrawal safely, that the dose will be guided by symptoms, and that this is treatment, not a reward. Avoid a confrontational or moralizing tone, which increases the risk of him leaving against advice.
3. How do you plan his discharge to prevent readmission and relapse?
Read the worked answer
Discharge planning:
- Complete the taper safely - do not discharge him on his prior alprazolam regimen without a plan; coordinate with his outside psychiatrist to consolidate prescribing and avoid duplicate benzodiazepine sources.
- Alcohol treatment linkage - referral to an addiction medicine or substance use program; consider naltrexone or acamprosate for alcohol use disorder after assessing liver function (naltrexone is hepatically metabolized; acamprosate is renally cleared).
- Medication reconciliation - ensure he leaves with a written list and a plan for obtaining medications; the admission was precipitated in part by not bringing his medications.
- Treat the anxiety underlying the alprazolam - coordinate with psychiatry for non-benzodiazepine options (SSRI, CBT) and a structured taper.
- Medical follow-up - liver disease evaluation, thrombocytopenia workup, and primary care follow-up.
- Social supports - screen for housing instability and social isolation, which drive relapse.
Judgment being tested: recognizing that safe discharge requires treating the substance use disorder and the prescribing fragmentation, not just the cellulitis.